Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL). In, Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7–10. San Antonio, TX Philadelphia (PA): AACR - Loirat, D; de Labarre, MD; Essner, C (Cancer Res, 2022)
et al.